Literature DB >> 15035653

Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup: in children aged between 5-11 years.

Vasundhara Tolia1, Gary Johnston, Julie Stolle, Chang Lee.   

Abstract

OBJECTIVE: To compare the flavor and taste preference of two acid-inhibitory therapies in healthy children aged between 5-11 years.
METHODS: A single-site, single-blind, taste test trial was conducted in which 111 children participated after parental consent. One teaspoonful (5 mL) of lansoprazole delayed-release oral suspension (strawberry-flavored) and ranitidine oral syrup (peppermint-flavored) were provided to each child with a 10-minute break between samples. Children tasted the sample, swished it in their mouth for 10 seconds, and then expectorated the sample. Spring water and crackers were used to clear the palate between samples. After each sampling, children were observed for facial expressions and asked to rate their degree of liking of each sample based on a 5-point facial hedonic scale (5=like it very much, 1=dislike it very much). Likes, dislikes, and product preference were recorded.
RESULTS: Of the 56 female and 54 male children who tasted both samples, 95% (105/110) preferred lansoprazole. Taste and flavor were the most often cited reasons for preferring lansoprazole (61 and 17 children, respectively) while three children preferred the flavor of ranitidine oral syrup. Lansoprazole received a higher mean liking rating compared with ranitidine (mean liking scores of 4.1 and 2.2, respectively). There was no significant difference in the preference for lansoprazole between age groups and gender with the degree of liking scores ranging between 3.5-4.4. Forty-two children disliked the texture of the lansoprazole oral suspension, citing the granules (31/110), thickness (7/110), or consistency/texture (4/110), specifically.
CONCLUSION: After sampling both products, 95% of children preferred the flavor and taste of the strawberry-flavored lansoprazole delayed-release oral suspension compared with the peppermint-flavored ranitidine oral syrup.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15035653     DOI: 10.2165/00148581-200406020-00006

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  33 in total

1.  Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.

Authors:  David Y Graham; Naurang M Agrawal; Donald R Campbell; Marian M Haber; Cyndy Collis; Nancy L Lukasik; Bidan Huang
Journal:  Arch Intern Med       Date:  2002-01-28

Review 2.  Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.

Authors:  L S Welage; R R Berardi
Journal:  J Am Pharm Assoc (Wash)       Date:  2000 Jan-Feb

3.  Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients.

Authors:  J L Powers; W M Gooch; L P Oddo
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

4.  Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

Authors:  C J Hawkey; J A Karrasch; L Szczepañski; D G Walker; A Barkun; A J Swannell; N D Yeomans
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

Review 5.  Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.

Authors:  M Lazzaroni; G Bianchi Porro
Journal:  Ital J Gastroenterol Hepatol       Date:  1999

Review 6.  Rabeprazole.

Authors:  A Prakash; D Faulds
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

7.  Efficacy and safety of omeprazole for severe gastroesophageal reflux in children.

Authors:  T S Gunasekaran; E G Hassall
Journal:  J Pediatr       Date:  1993-07       Impact factor: 4.406

8.  Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.

Authors:  A L Gough; R G Long; B T Cooper; C S Fosters; A D Garrett; C H Langworthy
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

9.  Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy.

Authors:  M Karjoo; R Kane
Journal:  Arch Pediatr Adolesc Med       Date:  1995-03

10.  Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers.

Authors:  D Matsui; A Barron; M J Rieder
Journal:  Ann Pharmacother       Date:  1996-06       Impact factor: 3.154

View more
  5 in total

Review 1.  Methodology Used to Assess Acceptability of Oral Pediatric Medicines: A Systematic Literature Search and Narrative Review.

Authors:  Punam Mistry; Hannah Batchelor
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

2.  Ranitidine (Zantac) syrup versus Ranitidine effervescent tablets (Zantac) EFFERdose) in children: a single-center taste preference study.

Authors:  Vanessa Z Ameen; Bonnie F Pobiner; Gregory C Giguere; Eric G Carter
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.

Authors:  Katherine F Croom; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children.

Authors:  Vasundhara Tolia; Cong Han; Janine D North; Fouad Amer
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

5.  Open-label taste-testing study to evaluate the acceptability of both strawberry-flavored and orange-flavored amylmetacresol/2,4-dichlorobenzyl alcohol throat lozenges in healthy children.

Authors:  Alex Thompson; Sandie Reader; Emma Field; Adrian Shephard
Journal:  Drugs R D       Date:  2013-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.